Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 57 #1
TickerABMD [NASD]
CompanyABIOMED, Inc.
CountryUSA
IndustryMedical Appliances & Equipment
Market Cap2.04BEPS (ttm)0.24
P/E208.08EPS this Y-51.40%
Forward P/E116.96EPS next Y168.55%
PEG9.68EPS past 5Y17.10%
P/S10.34EPS next 5Y21.50%
P/B11.51EPS Q/Q200.00%
Dividend-Sales Q/Q17.20%
Insider Own2.90%Inst Own-
Insider Trans-19.22%Inst Trans0.01%
Short Float9.78%EarningsJan 27/b
Analyst Recom2.20Target Price38.00
Avg Volume403.67K52W Range20.29 - 40.44
Jan-28-15Upgrade Northland Capital Under Perform → Market Perform
Jan-28-15 01:07PMAbiomed hits all-time high on sales, new device clearance AP
Jan-28-15 12:59PMMidday movers: Petrobras, Advent Software & more at CNBC
Jan-28-15 11:55AMAbiomed Stock Soars After Q3 Earnings Stomp Estimates at Investor's Business Daily
Jan-28-15 11:30AMAbiomed Q3 Earnings Impress; Impella RP Gets FDA Approval - Analyst Blog Zacks
Jan-28-15 11:23AMABIOMED (ABMD) Stock Soars Today on Third Quarter Earnings Beat at TheStreet
Jan-28-15 11:20AMAccuray (ARAY) Q2 Loss Wider than Expected, Revenues Lag - Analyst Blog Zacks
Jan-28-15 07:16AMABIOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
Jan-28-15 06:51AMAbiomed upgraded by Northland Capital Briefing.com
Jan-27-15 06:31PMUpdates, advisories and surprises at MarketWatch
Jan-27-15 06:13PMAbiomed shares jump on earnings beat, outlook at MarketWatch
ABIOMED, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. Its products consist of Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP, a micro heart pump; and Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. The company also manufactures and sells the Impella RP, a percutaneous catheter-based axial flow pump; and AB5000 circulatory support system and the BVS 5000 biventricular support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, it offers Symphony, a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics; and AbioCor program. The company sells its products through direct sales and clinical support personnel in the United States, Canada, Germany, France, the United Kingdom, and internationally. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Howley Michael GVP, Global Sales & MarketingApr 27Sale24.752,01649,89659,784Apr 30 03:08 PM
AUSTEN W GERALDDirectorJan 13Option Exercise18.6312,000223,56097,341Jan 15 05:23 PM
Greenfield Andrew JVP Healthcare SolutionsOct 31Option Exercise8.7715,000131,55067,639Nov 03 05:14 PM
Howley Michael GVP, Global Sales & MarketingOct 31Option Exercise5.8615,00087,90090,583Nov 03 05:14 PM
MINOGUE MICHAEL RPresident, CEO, ChairmanOct 31Option Exercise13.5782,0001,112,740300,803Nov 03 05:16 PM
TickerPSTI [NASD]
CompanyPluristem Therapeutics, Inc.
CountryIsrael
IndustryBiotechnology
Market Cap236.14MEPS (ttm)-0.43
P/E-EPS this Y-10.50%
Forward P/E-EPS next Y13.90%
PEG-EPS past 5Y7.80%
P/S590.34EPS next 5Y-
P/B4.32EPS Q/Q-12.50%
Dividend-Sales Q/Q-
Insider Own6.10%Inst Own1.70%
Insider Trans1.90%Inst Trans0.25%
Short Float0.79%Earnings-
Analyst Recom2.30Target Price5.00
Avg Volume141.75K52W Range2.32 - 4.36
Jan-27-15 04:00AMUpdated Coverage Report Focuses on Pluristem Therapeutics Marketwired
Jan-13-15 03:00AMPluristem to Present at Two Cell Therapy Conferences in January 2015 GlobeNewswire
Jan-12-15 01:42PMPLURISTEM THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Jan-12-15 03:00AMPluristem Issues Letter to Shareholders GlobeNewswire
Jan-06-15 03:30AMPluristem Granted Patent for Foundational Cell Harvesting Technology in South Africa GlobeNewswire
Dec-22-14 03:00AMNew Published Data Show Pluristem's PLX Cells Protect Neurons GlobeNewswire
Dec-04-14 03:00AMPluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes GlobeNewswire
Dec-01-14 03:00AMPluristem Granted Patent in Singapore for Its 3D Cell Expansion Technology GlobeNewswire
Nov-25-14 03:00AMPluristem's Dr. Ohad Karnieli to Present at Two Upcoming Scientific Conferences GlobeNewswire
Nov-21-14 07:15AMPluristem posts 1Q loss AP
Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions. Its patented PLacental eXpanded (PLX) cells function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals generated by the patient. The company's PLX cells are grown using proprietary 3D micro-environment technology that produces an off-the-shelf allogeneic cell therapy products. It also develops PLX-PAD cells, which are in Phase-II clinical trial for use in the treatment of peripheral and cardiovascular, orthopedic, and pulmonary diseases, as well as for hematological and women's health diseases; and PLX-RAD cells used for acute radiation syndrome treatment of animals, as well as products in pre-clinical trial for the treatment of pre-eclampsia and rotator-cuff repair. The company is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary arterial hypertension through its license agreement with the United Therapeutics Corporation; and commercialization agreement with CHA Bio&Diostech for conducting clinical trials and commercialization of PLX-PAD products in South Korea. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aberman ZamiCEO & ChairmanNov 11Buy2.6413,00034,2551,768,298Nov 12 08:20 AM
YANAY YAKYCOO & PresidentNov 11Buy2.6211,00028,7901,101,616Nov 12 08:14 AM
Aberman ZamiCEO & ChairmanSep 22Buy2.925,00014,6001,755,298Sep 23 10:52 AM
YANAY YAKYCOO & PresidentSep 22Buy2.9511,00032,4501,090,616Sep 23 10:53 AM
Aberman ZamiCEO & ChairmanSep 21Buy2.965,00014,7751,750,298Sep 22 08:07 AM
TickerPBM [AMEX]
CompanyPacific Booker Minerals Inc.
CountryCanada
IndustryIndustrial Metals & Minerals
Market Cap57.51MEPS (ttm)-0.12
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B2.30EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float0.04%Earnings-
Analyst Recom-Target Price-
Avg Volume6.34K52W Range3.11 - 6.69
Jun-06-14 01:04PMPACIFIC BOOKER MINERALS INC. Financials EDGAR Online Financials
May-28-14 11:30AMPacific Booker Minerals - An Intriguing But Sad Story at Seeking Alpha
Pacific Booker Minerals Inc. is engaged in the exploration of mineral property interests in Canada. It primarily holds interest in the Morrison Project, a copper/gold exploration project covering an area of 65 square kilometers located in British Columbia. The company was formerly known as Booker Gold Explorations Limited and changed its name to Pacific Booker Minerals Inc. in February 2000. Pacific Booker Minerals Inc. was incorporated in 1983 and is headquartered in Vancouver, Canada.
TickerAETI [NASD]
CompanyAmerican Electric Technologies, Inc
CountryUSA
IndustryIndustrial Electrical Equipment
Market Cap43.76MEPS (ttm)0.02
P/E267.50EPS this Y76.00%
Forward P/E10.92EPS next Y1325.00%
PEG-EPS past 5Y14.90%
P/S0.71EPS next 5Y-
P/B1.88EPS Q/Q-308.30%
Dividend-Sales Q/Q-11.70%
Insider Own29.90%Inst Own33.20%
Insider Trans-1.71%Inst Trans-276.10%
Short Float1.08%EarningsNov 11
Analyst Recom1.00Target Price7.50
Avg Volume9.32K52W Range4.09 - 9.96
Dec-11-14 08:50AMAmerican Electric Tech (AETI) Downgraded From Buy to Hold at TheStreet
Nov-21-14 01:04PMAMERICAN ELECTRIC TECHNOLOGIES INC Financials EDGAR Online Financials
Nov-17-14 07:09PM10-Q for American Electric Technologies, Inc. Company Spotlight
Nov-14-14 10:01AMAMERICAN ELECTRIC TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial State EDGAR Online
Nov-12-14 12:00PMAmerican Electric Technologies CEO to Present at Southwest IDEAS Investor Conference GlobeNewswire
Nov-11-14 07:07AMQ3 2014 American Electric Technologies Inc Earnings Release - Time Not Supplied CCBN
Nov-11-14 07:00AMAETI Records $1.5 Million Quarterly Loss Before One-Time Expenses and Announces Record Backlog GlobeNewswire
Nov-06-14 11:12AMAmerican Electric Technologies to Report Third Quarter 2014 Results GlobeNewswire
Sep-08-14 05:25PMAMERICAN ELECTRIC TECHNOLOGIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Finan EDGAR Online
Aug-20-14 02:02PMAMERICAN ELECTRIC TECHNOLOGIES INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial EDGAR Online
American Electric Technologies, Inc. provides power delivery solutions to the energy industry in the United States and internationally. It operates in three segments: Technical Products and Services (TP&S), Electrical and Instrumentation Construction (E&I), and American Access Technologies (AAT). The TP&S segment designs, manufactures, markets, and provides low and medium voltage switchgears, generator control and distribution switchgears, motor control centers, powerhouses, bus ducts, variable frequency AC drives, variable speed DC drives, program logic control based automation systems, human machine interface, and specialty panels to distribute the flow of electricity and protect electrical equipment, such as motors, transformers, and cables. It also offers services, such as electrical equipment retrofits, upgrades, start-ups, testing, and troubleshooting of substations, switchgear, drives, and control systems. The E&I segment provides electrical and instrumentation construction and installation services to land and marine based markets of the oil and gas, and other commercial and industrial markets. Its services include electrical and instrumentation turnarounds, maintenance, renovation, and new construction; and marine based oil and gas services, such as electrical system rig-ups, modifications, and start-ups, as well as testing for vessels, drilling rigs, and production modules. The AAT segment manufactures and markets zone cabling and wireless telecommunication enclosures, and formed metals products; operates a precision sheet metal fabrication and assembly operation; and provides services, such as precision computer numerical controlled stamping, bending, assembling, painting, powder coating, and silk screening to engineering, technology, and electronics companies. The company is headquartered in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Steffek James JSVP of Sales and Business Dev.Dec 04Sale5.8820,000117,690623,024Dec 08 04:30 PM
Dauber Arthur G10% OwnerNov 25Sale5.8822,500132,3001,305,885Nov 26 04:08 PM
Puhala Andrew LewisSenior Vice President & CFOMar 14Option Exercise0.003,49800Mar 20 06:07 PM
Dauber Charles MPresident and CEOFeb 19Option Exercise4.094,15016,97447,020Feb 19 10:41 AM
TickerFSL [NYSE]
CompanyFreescale Semiconductor, Ltd.
CountryUSA
IndustrySemiconductor - Broad Line
Market Cap9.47BEPS (ttm)0.15
P/E207.73EPS this Y-97.60%
Forward P/E17.35EPS next Y22.59%
PEG13.85EPS past 5Y52.40%
P/S2.05EPS next 5Y15.00%
P/B-EPS Q/Q344.40%
Dividend-Sales Q/Q11.80%
Insider Own0.50%Inst Own40.40%
Insider Trans-7.75%Inst Trans0.27%
Short Float6.73%EarningsJan 27/a
Analyst Recom2.20Target Price28.50
Avg Volume2.37M52W Range15.08 - 27.28
Jan-28-15Upgrade Needham Buy → Strong Buy $45
Jan-28-15Reiterated RBC Capital Mkts Outperform $28 → $33
Jan-28-15Reiterated Barclays Equal Weight $25 → $27
Jan-28-15Reiterated Deutsche Bank Buy $30 → $35
Jan-28-15 04:46PMWednesday's Market Recap Yahoo Finance Contributors
Jan-28-15 12:48PMStory Stocks from Briefing.com Briefing.com
Jan-28-15 10:12AMFreescale Semiconductor (FSL) Stock Surging Today as Earnings Top Estimates at TheStreet
Jan-28-15 09:49AM9:49 am Freescale Semi (+24%) at new all time high following beat and raise report last night Briefing.com
Jan-28-15 09:10AMTechs Haul Stock Futures Higher; Apple, Yahoo, Freescale Soar at Investor's Business Daily
Jan-28-15 07:40AMFreescale Semi upgraded by Needham Briefing.com
Jan-27-15 07:26PMFreescale revenue outlook pushes shares higher as CEO talks cars Reuters
Jan-27-15 05:10PMFreescale Semiconductor posts 4Q profit AP
Jan-27-15 04:26PMFREESCALE SEMICONDUCTOR, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
Jan-27-15 04:05PMFreescale Semiconductor Announces Fourth Quarter and Full-Year 2014 Results Business Wire
Freescale Semiconductor, Ltd. provides embedded processing solutions for automotive, networking, industrial, and consumer markets worldwide. The company's embedded processor products comprise microcontrollers, such as ultra low power, low end 8-bit products to higher performance 16-bit, and 32-bit products with on-board flash memory, which provide the digital logic or intelligence for electronic applications and controlling electronic equipment; single-and multi-core microprocessors; and applications processors with embedded memory, and special purpose hardware and software for multimedia applications. It also offers wireless connectivity products for low power wireless communications functionality; communications processors that perform tasks related to control and management of digital data, and network interfaces; and radio frequency devices, such as power transistors, amplifiers, receivers, and tuners. In addition, the company provides analog and mixed-signal products, such as system-basis chips, auto engine control, stability and braking solutions, battery and power management, and motor control devices, CAN/LIN interface solutions, radar solutions, and signal conditioners; and sensors comprising pressure, inertial, magnetic, proximity, and gyroscopic sensors. Further, the company offers digital signal processors to perform baseband modem processing; digital signal controllers, which offer solutions for digital power conversion, motor control, and other applications in consumer, industrial, and healthcare markets. It serves original equipment manufacturers, distributors, original design manufacturers, and contract manufacturers through its direct sales force and distributors. The company was formerly known as Freescale Semiconductor Holdings I, Ltd. and changed its name to Freescale Semiconductor, Ltd. in April 2012. The company was incorporated in 2006 and is based in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wuamett JenniferSVP, GC and SecretaryJan 12Sale26.4299226,21136,510Jan 14 06:51 PM
Elson Jeffrey RSVP, HR and SecurityJan 12Sale26.422,71471,71059,973Jan 14 06:47 PM
Wuamett JenniferSVP, GC and SecretaryJan 07Sale24.2449912,09837,502Jan 07 07:42 PM
Bates JamesSVP & GM, Analog & SensorsJan 06Sale24.091,88845,49080,658Jan 07 07:02 PM
CONRAD ROBERT JSVP, GM Automotive MCUsJan 06Sale24.111,73441,804102,317Jan 07 07:07 PM
TickerSMLR [NASD]
CompanySemler Scientific Inc
CountryUSA
IndustryMedical Appliances & Equipment
Market Cap17.34MEPS (ttm)-1.01
P/E-EPS this Y19.70%
Forward P/E-EPS next Y36.50%
PEG-EPS past 5Y0.00%
P/S5.10EPS next 5Y-
P/B3.77EPS Q/Q-181.80%
Dividend-Sales Q/Q50.00%
Insider Own43.63%Inst Own13.20%
Insider Trans-1.35%Inst Trans-15.87%
Short Float0.14%Earnings-
Analyst Recom2.50Target Price12.00
Avg Volume11.74K52W Range1.81 - 7.25
Jan-28-15 08:00AMSemler to Report Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on February 6, 2015 PR Newswire
Dec-08-14 08:30AMSemler Scientific, Inc. Presentation Now Available for On-Demand viewing at VirtualInvestorConferences.com CNW Group
Dec-08-14 08:30AMSemler Scientific, Inc. Presentation Now Available for On-Demand viewing at VirtualInvestorConferences.com PR Newswire
Dec-02-14 08:29AMEight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com PR Newswire
Dec-02-14 08:29AMEight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com CNW Group
Nov-21-14 08:30AMSemler Scientific, Inc., to Webcast, Live, at VirtualInvestorConferences.com December 4th CNW Group
Nov-21-14 08:30AMSemler Scientific, Inc., to Webcast, Live, at VirtualInvestorConferences.com December 4th PR Newswire
Nov-03-14 04:08PMSEMLER SCIENTIFIC, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E EDGAR Online
Nov-03-14 04:02PMSEMLER SCIENTIFIC, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Oct-31-14 08:00AMSemler Reports Third Quarter 2014 Financial Results PR Newswire
Semler Scientific, Inc., a medical risk-assessment company, develops, manufactures, and markets various patented products to identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services in the United States. Its products include FloChec that is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a useful tool for internists and primary care physicians. The company provides its FloChec product and services to its customers through its salespersons and through its co-exclusive distributor. Semler Scientific, Inc. was founded in 2007 and is headquartered in Portland, Oregon.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Murphy-Chutorian DouglasChief Executive OfficerNov 05Buy2.101,0002,10061,471Nov 05 09:02 PM
Murphy-Chutorian DouglasChief Executive OfficerNov 04Buy2.101,0002,10060,471Nov 05 09:02 PM
Semler Herbert JDirectorSep 12Sale3.2530,00097,500557,891Sep 12 06:24 PM
TickerEXEL [NASD]
CompanyExelixis, Inc.
CountryUSA
IndustryBiotechnology
Market Cap398.23MEPS (ttm)-1.47
P/E-EPS this Y-44.60%
Forward P/E-EPS next Y37.30%
PEG-EPS past 5Y2.90%
P/S18.02EPS next 5Y-
P/B-EPS Q/Q11.10%
Dividend-Sales Q/Q14.50%
Insider Own1.80%Inst Own63.30%
Insider Trans0.57%Inst Trans-4.09%
Short Float25.42%EarningsFeb 24/a
Analyst Recom2.50Target Price2.33
Avg Volume2.47M52W Range1.26 - 7.58
Jan-07-15 08:30AMExelixis and Swedish Orphan Biovitrum AB (Sobi) Extend and Restructure Distribution Agreement for COMETRIQ® for Medullary Thyroid Cancer Business Wire
Dec-15-14 01:00AMExelixis Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma Business Wire
Dec-05-14 05:16PMEXELIXIS, INC. Files SEC form 8-K, Other Events EDGAR Online
Dec-02-14 01:29PMExelixis Shares Down on COMET-2 Study Results on Cabozantinib Zacks
Dec-01-14 11:37AMFuture of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study at TheStreet
Dec-01-14 08:00AMExelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With Metastatic Castration-Resistant Prostate Cancer Business Wire
Nov-25-14 04:05PMExelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2 Business Wire
Nov-16-14 04:20AMExelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib Business Wire
Nov-14-14 01:04PMEXELIXIS, INC. Financials EDGAR Online Financials
Nov-11-14 04:40PMExelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18 Business Wire
Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BURKE DEBORAHSVP & Chief Financial OfficerNov 15Option Exercise0.006,438019,377Nov 18 06:52 PM
Lamb PeterEVP, Discovery Research & CSONov 15Option Exercise0.002,083037,237Nov 18 06:55 PM
Schwab GiselaEVP and Chief Medical OfficerNov 15Option Exercise0.003,125078,730Nov 18 06:57 PM
MARCHESI VINCENT TDirectorSep 17Buy1.7120,00034,19945,000Sep 19 05:05 PM
Schwab GiselaEVP and Chief Medical OfficerFeb 15Option Exercise0.002,188071,494Feb 18 09:30 PM
TickerANFI [NYSE]
CompanyAmira Nature Foods Ltd.
CountryUnited Arab Emirates
IndustryFood - Major Diversified
Market Cap370.70MEPS (ttm)1.08
P/E11.97EPS this Y65.10%
Forward P/E8.17EPS next Y14.05%
PEG0.62EPS past 5Y0.00%
P/S0.64EPS next 5Y19.30%
P/B4.72EPS Q/Q19.00%
Dividend-Sales Q/Q25.80%
Insider Own-Inst Own37.30%
Insider Trans-Inst Trans-0.01%
Short Float56.57%EarningsFeb 23/a
Analyst Recom2.30Target Price20.75
Avg Volume242.31K52W Range9.50 - 25.00
Jan-28-15 03:50PMAmira Nature Foods Ltd -- Moody's assigns B2 CFR to Amira; stable outlook at Moody's
Jan-28-15 01:20PM1:20 pm Amira Nature Foods announces offering of $225 mln senior secured second lien notes and $35 mln senior secured revolving credit facility Briefing.com
Jan-28-15 01:20PMAmira Nature Foods Ltd Announces Offering of $225 Million Senior Secured Second Lien Notes and $35 Million Senior Secured Revolving Credit Facility Business Wire
Jan-07-15 10:27AMUPDATE: Oppenheimer Initiates Coverage On Amira Nature Foods On Still Undiscovered Natural/Organic Global Play Benzinga
Jan-07-15 07:53AMCoverage initiated on Amira Nature Foods by Oppenheimer Briefing.com
Dec-29-14 09:19AMAmira Nature Foods Ltd Announces $90 Million Contract with Repeat Customer Business Wire
Dec-24-14 10:54AMAmira Nature Foods (ANFI) Stock Spiking Today on Guidance Hike at TheStreet
Dec-24-14 09:52AMAmira Nature Foods Ltd Raises Fiscal 2015 Guidance Business Wire
Dec-18-14 10:00AMAmira Nature Foods (ANFI) Downgraded From Buy to Hold at TheStreet
Dec-16-14 04:01PMAmira to Participate in Upcoming Global Food Shows Business Wire
Amira Nature Foods Ltd is engaged in processing, distributing, and marketing packaged specialty rice and other food products. The company provides various types of basmati rice, specialty rice and value add meals, ready-to-eat snacks, ready to heat means, edible oils, organics, and dairy products for retailers under the Amira brand; and non-basmati rice. It also sells bulk commodities, including wheat, barley, legume, maize, sugar, soybean meal, onion, potatos, and millets to trading firms. Amira Nature Foods Ltd sells its products to distributors and retail chains in India; and buyers in the Asia Pacific, the Middle East, Europe, North Africa, and North America. The company was founded in 1915 and is based in Dubai, the United Arab Emirates.
TickerTBIO [NASD]
CompanyTransgenomic Inc.
CountryUSA
IndustryScientific & Technical Instruments
Market Cap28.47MEPS (ttm)-1.79
P/E-EPS this Y-48.40%
Forward P/E-EPS next Y-18.90%
PEG-EPS past 5Y0.00%
P/S1.11EPS next 5Y20.00%
P/B2.53EPS Q/Q93.60%
Dividend-Sales Q/Q-3.00%
Insider Own20.86%Inst Own28.50%
Insider Trans0.00%Inst Trans-7.08%
Short Float0.08%Earnings-
Analyst Recom2.00Target Price10.00
Avg Volume56.18K52W Range1.41 - 6.49
Jan-20-15 05:00PMTRANSGENOMIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti EDGAR Online
Jan-14-15 05:27PMTRANSGENOMIC INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits EDGAR Online
Jan-14-15 08:00AMTransgenomic Announces Q1 2015 Launch of Its Multiplexed Ice Cold-PCRTM Technology That Enables Wide Use of Liquid Biopsies and Personalized Medicine Business Wire
Jan-08-15 08:00AMTransgenomic to Present at OneMedForum San Francisco 2015 Conference Business Wire
Jan-07-15 04:18PMTRANSGENOMIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti EDGAR Online
Dec-23-14 06:03AMTRANSGENOMIC INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Dec-11-14 08:32AMTRANSGENOMIC INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Nov-21-14 01:04PMTRANSGENOMIC INC Financials EDGAR Online Financials
Nov-19-14 07:30AMTransgenomic Collaborates with Researchers to Advance Understanding of Genetic Disease Tuberous Sclerosis Business Wire
Nov-14-14 07:09PM10-Q for Transgenomic, Inc. Company Spotlight
Transgenomic, Inc. operates as a biotechnology company that focuses advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and clinical and research services in the United States, Italy, the United Kingdom, Germany, France, and internationally. It operates in two segments, Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. This segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies. It employs various genomic testing service technologies, including ICE COLD-PCR technology, a proprietary platform technology that enables detection of multiple unknown mutations from virtually any sample type, including tissue biopsies, blood, cell-free DNA, and circulating tumor cells. The Genetic Assays and Platforms segment offers the WAVE System, which has applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. The company sells its products through direct sales, support staff, dealers, and distributors to academic and medical institutions; and pharmaceutical, biotech, and commercial companies. Transgenomic, Inc. has a strategic collaboration agreement with PDI, Inc. The company was founded in 1997 and is headquartered in Omaha, Nebraska.
TickerEA [NASD, S&P 500]
CompanyElectronic Arts Inc.
CountryUSA
IndustryMultimedia & Graphics Software
Market Cap16.98BEPS (ttm)1.12
P/E48.76EPS this Y-90.30%
Forward P/E23.18EPS next Y12.57%
PEG2.99EPS past 5Y15.00%
P/S4.11EPS next 5Y16.30%
P/B6.40EPS Q/Q101.10%
Dividend-Sales Q/Q42.40%
Insider Own0.40%Inst Own99.90%
Insider Trans-16.87%Inst Trans0.37%
Short Float5.26%EarningsJan 27/a
Analyst Recom2.10Target Price47.06
Avg Volume4.06M52W Range24.44 - 50.41
Jan-28-15Reiterated Brean Capital Buy $54 → $57
Jan-28-15Reiterated Stifel Buy $53 → $59
Jan-28-15Reiterated Needham Buy $51 → $58
Jan-28-15Reiterated MKM Partners Neutral $48 → $54
Jan-28-15Reiterated Barclays Overweight $48 → $56
Jan-28-15Reiterated UBS Neutral $50 → $52
Jan-28-15 08:55PMEA soars to 7-year high on holiday game sales at Investor's Business Daily
Jan-28-15 05:33PMElectronic Arts Surges on Growth Potential, Apple Jumps Following Earnings: Tech Winners & Losers at TheStreet
Jan-28-15 04:46PMWednesday's Market Recap Yahoo Finance Contributors
Jan-28-15 04:37PMElectronic Arts is Priced for a Perfect Game at The Wall Street Journal
Jan-28-15 03:00PMStock Indexes Turn Mixed; Apple Stays Strong at Investor's Business Daily
Jan-28-15 02:49PMElectronic Arts Surges On Success Of Digital Games at Forbes
Jan-28-15 01:45PMWhy Analysts Are Loving EA More and More After Earnings at 24/7 Wall St.
Jan-28-15 12:55PMEA Is Making A Killing Off The DLC You Hate at Forbes
Jan-28-15 12:54PMMobile games success boosts Electronic Arts at Financial Times
Jan-28-15 11:58AMBoeing takes off, EA scores with profits and WWE smackdown Yahoo Finance
Electronic Arts Inc. develops, markets, publishes, and distributes game software content and services for video game consoles, personal computers, mobile phones, and tablets. The company operates through EA Games, EA SPORTS, Maxis, PopCap, and All Play segments. It provides action-adventure, casual, family, fantasy, first-person shooter, horror, science fiction, role-playing, racing, simulation, sports, and strategy games under the Battlefield, Mass Effect, Need for Speed, Dragon Age, The Sims, Bejeweled, and Plants v. Zombies, as well as EA SPORTS, Battlefield 4, FIFA Street, Maxis, Madden NFL, Medal of Honor, and Star Wars brand names. The company also offers casual games, such as cards, puzzles, and word games through its pogo.com, as well as on other platforms; and digital content and Internet-based advertising services. The company was founded in 1982 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jorgensen Blake JEVP & Chief Financial OfficerJan 05Sale46.943,909183,47372,342Jan 05 06:44 PM
Jorgensen Blake JEVP & Chief Financial OfficerDec 01Sale43.673,909170,70676,251Dec 01 05:30 PM
LINZNER JOELEVP Legal & Business AffairsNov 25Sale44.50251,113179,625Nov 26 04:01 PM
LINZNER JOELEVP Legal & Business AffairsNov 21Sale44.002,500110,000179,650Nov 21 05:25 PM
LINZNER JOELEVP Legal & Business AffairsNov 19Sale43.495,000217,464182,150Nov 20 05:48 PM
1 2 3 4 5 6 next